Baxter Appoints New CEO as Company Emerges from Restructuring

Baxter International Inc., a leading global medical products company, has announced the appointment of Andrew Hider as its new President and Chief Executive Officer. This strategic move comes as the company concludes a significant restructuring phase, marking a new era for the healthcare giant.

Leadership Transition and Corporate Strategy

Andrew Hider, formerly the CEO of ATS Corporation, is set to take the helm at Baxter by September 3, 2025. Hider's appointment follows the retirement of long-time chief José Almeida in February. The selection of Hider aligns with Baxter's focus on accelerating growth and innovation in the medical technology sector.

During his tenure at ATS, a provider of factory automation solutions across multiple industries including life sciences, Hider demonstrated a strong track record of operational excellence and value creation. Under his leadership, ATS nearly doubled its adjusted revenue over five fiscal years while restructuring and pivoting its portfolios.

Brent Shafer, who served as interim CEO since Almeida's retirement, expressed confidence in Hider's ability to lead Baxter into its next chapter. "Andrew is an exceptional leader with a strong track record of operational excellence, disciplined execution and innovation," Shafer stated.

Baxter's Transformation and Future Outlook

Baxter has undergone significant changes in recent years, refocusing its business and streamlining operations. The company's restructuring efforts included the sale of its Vantive kidney care unit to The Carlyle Group for $3.8 billion and the divestment of its biopharma solutions business to private equity firms Warburg Pincus and Advent International for $4.25 billion.

These strategic moves have positioned Baxter as a leaner, more focused entity in the medical technology landscape. The company aims to leverage this newfound agility to drive innovation and enhance its market position.

Hider commented on his new role, saying, "Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future. I look forward to partnering with the Board and working alongside my talented future colleagues to accelerate innovation, further enhance our performance and redefine healthcare delivery while driving sustainable, long-term growth."

As Baxter enters this new phase, industry observers will be closely watching how Hider's experience in automation and operational efficiency will translate to the medical technology sector, and how it will shape Baxter's strategy in an increasingly competitive and innovation-driven market.